Resistance Genes and Molecular Epidemiology in Ceftazidime-Avibactam-Resistant Pseudomonas aeruginosa Isolates

Resistance Genes and Molecular Epidemiology in Ceftazidime-Avibactam-Resistant Pseudomonas aeruginosa Isolates

Introduction: Increasing ceftazidime-avibactam (CZA) resistance in P. aeruginosa isolates is of serious concern worldwide. Therefore, studies on the underlying resistance mechanisms gain even more importance. The aim of this study was to investigate the presence of beta-lactamase genes reported to b...

Full description

Bibliographic Details
Main Authors:	Neslihan ARICI, Elif Seren TANRIVERDİ
Format:	Article
Language:	Turkish
Published:	Galenos Yayinevi 2023-10-01
Series:	Mediterranean Journal of Infection, Microbes and Antimicrobials
Subjects:	pseudomonas aeruginosa ceftazidime-avibactam resistance metallo-beta-lactamases pfge
Online Access:	https://mjima.org/text.php?&id=393

Similar Items

In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany
by: Michael Kresken, et al.
Published: (2021-06-01)

Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria
by: Michaela Simon, et al.
Published: (2022-11-01)

Emergence of Ceftazidime- and Avibactam-Resistant Klebsiella pneumoniae Carbapenemase-Producing Pseudomonas aeruginosa in China
by: Yiwei Zhu, et al.
Published: (2021-12-01)

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
by: María M. Montero, et al.
Published: (2021-09-01)

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection
by: Chen J, et al.
Published: (2022-02-01)

Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
by: María Fernanda Mojica, et al.
Published: (2023-04-01)

Prevalence and molecular characteristics of ceftazidime-avibactam resistance among carbapenem-resistant Pseudomonas aeruginosa clinical isolates
by: Yili Chen, et al.
Published: (2024-03-01)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
by: Leilei Wang, et al.
Published: (2023-06-01)

Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients
by: Chen J, et al.
Published: (2023-04-01)

Ceftazidime-avibactam and comparators against Pseudomonas aeruginosa isolates collected globally and in each geographical region between 2017–2020
by: Pattarachai Kiratisin, et al.
Published: (2023-09-01)

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam
by: Atkin SD, et al.
Published: (2018-09-01)

Genomic Analysis of Ceftazidime/Avibactam-Resistant GES-Producing Sequence Type 235 <i>Pseudomonas aeruginosa</i> Isolates
by: Raúl Recio, et al.
Published: (2022-06-01)

Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa
by: Yixin Kang, et al.
Published: (2023-06-01)

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185
by: Akito Kawai, et al.
Published: (2024-02-01)

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
by: Baharak Babouee Flury, et al.
Published: (2023-04-01)

Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa
by: Yulin Zhang, et al.
Published: (2022-04-01)

A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)–producing Enterobacterales infection
by: Timothy Miles Rawson, et al.
Published: (2022-06-01)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
by: Alessandro Mancuso, et al.
Published: (2023-08-01)

First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran
by: Rahimzadeh M, et al.
Published: (2020-02-01)

Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015‒2020
by: Mark G. Wise, et al.
Published: (2023-05-01)

Resistance to ceftazidime–avibactam and underlying mechanisms
by: Yuhang Wang, et al.
Published: (2020-09-01)

Ceftazidime-avibactam: new rules for the game against multidrug-resistant gram-negative bacteria
by: Kozlov R.S., et al.
Published: (2018-02-01)

Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital
by: C. Weber, et al.
Published: (2022-10-01)

Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing Enterobacterales
by: Yanis Merad, et al.
Published: (2023-08-01)

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
by: Helio S. Sader, et al.
Published: (2021-12-01)

<italic toggle="yes">Klebsiella pneumoniae</italic> Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering
by: Melissa D. Barnes, et al.
Published: (2017-11-01)

Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative Bacteria
by: Tingting Xu, et al.
Published: (2022-04-01)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
by: Zeyu Huang, et al.
Published: (2023-11-01)

In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017–2021
by: Mark G. Wise, et al.
Published: (2023-12-01)

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
by: María José Contreras-Gómez, et al.
Published: (2022-10-01)

Metallo-β-lactamase-producing Pseudomonas aeruginosa in two hospitals from southern Brazil
by: Fernanda W. Wirth, et al.

Dynamic Emergence of Mismatch Repair Deficiency Facilitates Rapid Evolution of Ceftazidime-Avibactam Resistance in <named-content content-type="genus-species">Pseudomonas aeruginosa</named-content> Acute Infection
by: Pavel P. Khil, et al.
Published: (2019-10-01)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
by: Marianna Meschiari, et al.
Published: (2021-10-01)

A Simple Disk Stacking Plus Micro-Elution Method for Rapid Detection of the Synergistic Effect of Aztreonam and Ceftazidime/Avibactam Against Metallo-β-Lactamase Producing Enterobacterales
by: Liu Z, et al.
Published: (2023-03-01)

Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i>: In Vivo and In Vitro Evidence
by: Inmaculada Lopez-Montesinos, et al.
Published: (2022-10-01)

Identification of São Paulo metallo-beta-lactamase-1-producing Pseudomonas aeruginosa in the Central-West region of Brazil: a case study
by: Wirlaine Glauce Maciel, et al.

The <i>Klebsiella pneumoniae</i> carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam
by: Sona Garsevanyan, et al.
Published: (2023-12-01)

Antibiotic resistance pattern and evaluation of metallo-beta lactamase genes (VIM and IMP) in Pseudomonas aeruginosa strains producing MBL enzyme, isolated from patients with secondary immunodeficiency
by: Kiana Shirani, et al.
Published: (2016-01-01)

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i>
by: George L. Daikos, et al.
Published: (2021-09-01)

Emergence of a KPC-90 Variant that Confers Resistance to Ceftazidime-Avibactam in an ST463 Carbapenem-Resistant Pseudomonas aeruginosa Strain
by: Yuexing Tu, et al.
Published: (2022-02-01)